Idarubicin hydrochloride
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1990
- First approval year
- 1990
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Idarubicin hydrochloride
- Molecular weight
- 533.96
- Structure (SMILES)
- CC(=O)[C@]1(O)Cc2c(O)c3c(c(O)c2[C@@H](O[C@H]2C[C@H](N)[C@H](O)[C@H](C)O2)C1)C(=O)c1ccccc1C3=O.Cl
- idamycin
- Idamycin
- idamycin pfs
- Idamycin pfs
- idarubicin hydrochloride
- Idarubicin hydrochloride
- idarubicin hydrochloride pfs
- Idarubicin hydrochloride pfs
- zavedos
- Zavedos
- 1s 3s 3 acetyl 1 2 3 4 6 11 hexahydro 3 5 12 trihydroxy 6 11 dioxo 1 naphthacenyl 3 amino 2 3 6 trideoxy alpha l lyxo hexopyranoside hydrochloride
- 1S,3S)-3-ACETYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSIDE, HYDROCHLORIDE
- 5 12 naphthacenedione 9 acetyl 7 3 amino 2 3 6 trideoxy alpha l lyxo hexopyranosyl oxy 7 8 9 10 tetrahydro 6 9 11 trihydroxyhydrochloride 7s cis
- 5,12-NAPHTHACENEDIONE, 9-ACETYL-7-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,9,11-TRIHYDROXYHYDROCHLORIDE, (7S-CIS)-
- idarubicin hcl
- Idarubicin hcl
- idarubicin hydrochloride
- Idarubicin hydrochloride
- IDARUBICIN HYDROCHLORIDE [JAN]
- IDARUBICIN HYDROCHLORIDE [MART.]
- IDARUBICIN HYDROCHLORIDE [MI]
- IDARUBICIN HYDROCHLORIDE [ORANGE BOOK]
- IDARUBICIN HYDROCHLORIDE [USAN]
- IDARUBICIN HYDROCHLORIDE [USP MONOGRAPH]
- IDARUBICIN HYDROCHLORIDE [USP-RS]
- IDARUBICIN HYDROCHLORIDE [VANDF]
- Idarubicin hydrochloride [WHO-DD]
- idarubicin hydrochloride jan
- idarubicin hydrochloride mart
- idarubicin hydrochloride mi
- idarubicin hydrochloride orange book
- idarubicin hydrochloride usan
- idarubicin hydrochloride usp monograph
- idarubicin hydrochloride usp rs
- idarubicin hydrochloride vandf
And 6 more, listed on the interactive page.
- ATC classification codes
- L01DB06
Sources for recorded values
- CAS registry numbers
- 57852-57-0
- ChEMBL ID
- CHEMBL1200976
- InChIKey
- JVHPTYWUBOQMBP-RVFAQHLVSA-N
- PubChem compound IDs
- 636362
- FDA ingredient codes (UNII)
- 5VV3MDU5IE
- 5650
- 82124
- Applicant
- PFIZER
- Approval date
- 17 Feb 1997
- Application number
- NDA050734
- Patents
- 0
- Designations
- 2
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- Yes
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Prescription only
- Boxed warning
- Yes
- Pharmacology name
- idarubicin
- Type
- Natural product
- Drug name stem
- -rubicin
Administration routes
- Parenteral
- Mechanism
- DNA inhibitor
- Action type
- Inhibitor
- Target
- DNA
- Mechanism
- DNA topoisomerase II alpha inhibitor
- Action type
- Inhibitor
- Target
- DNA topoisomerase 2-alpha
- Protein identifier
- P11388
Open Targets mechanisms
- Mechanism
- DNA topoisomerase II alpha inhibitor
- Action type
- Inhibitor
- Target
- DNA topoisomerase 2-alpha
- Condition
- Carcinoma, Hepatocellular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000182
- Subject identifier
- D006528
- Condition
- Leukemia, Myeloid, Acute
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000222
- Subject identifier
- D015470
- Condition
- Leukemia, Myeloid
- Highest recorded phase
- 2
- Condition identifier
- MONDO:0004643
- Subject identifier
- D007951
- Condition identifier
- EFO_0000182
- Condition identifier
- EFO_0000222
- Condition identifier
- MONDO_0007256
- Condition identifier
- MONDO_0018874
- Highest recorded phase
- 4
- Condition identifier
- MONDO_0018881
- Highest recorded phase
- 2
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Warning
- Black Box Warning
- Effect
- cardiotoxicity
- Country
- United States
- Warning
- Black Box Warning
- Effect
- hematological toxicity
- Country
- United States
- Event
- acute lymphocytic leukaemia recurrent
- Reports
- 6
- Reporting signal score
- 15.2333
- Event
- acute motor-sensory axonal neuropathy
- Reports
- 5
- Reporting signal score
- 20.2637
- Event
- acute myeloid leukaemia
- Reports
- 46
- Reporting signal score
- 135.594
- Event
- acute myeloid leukaemia recurrent
- Reports
- 6
- Reporting signal score
- 19.8485
- Event
- acute promyelocytic leukaemia differentiation syndrome
- Reports
- 4
- Reporting signal score
- 14.5751
- Event
- aeromonas infection
- Reports
- 4
- Reporting signal score
- 18.0798
- Event
- aplasia
- Reports
- 15
- Reporting signal score
- 47.7265
- Event
- arthralgia
- Reports
- 2
- Reporting signal score
- 18.0875
- Event
- aspergillosis
- Reports
- 6
- Reporting signal score
- 19.2702
- Event
- bacteraemia
- Reports
- 12
- Reporting signal score
- 17.7834
- Event
- blood bilirubin increased
- Reports
- 16
- Reporting signal score
- 14.4538
- Event
- bone marrow failure
- Reports
- 52
- Reporting signal score
- 108.412
- Event
- bronchopulmonary aspergillosis
- Reports
- 19
- Reporting signal score
- 49.3807
- Event
- chronic myelomonocytic leukaemia
- Reports
- 5
- Reporting signal score
- 17.4143
- Event
- cytarabine syndrome
- Reports
- 3
- Reporting signal score
- 16.8929
- Event
- cytogenetic abnormality
- Reports
- 19
- Reporting signal score
- 77.4156
- Event
- disseminated intravascular coagulation
- Reports
- 14
- Reporting signal score
- 24.1789
- Event
- dizziness
- Reports
- 5
- Reporting signal score
- 18.4457
- Event
- drug hypersensitivity
- Reports
- 1
- Reporting signal score
- 17.113
- Event
- ejection fraction decreased
- Reports
- 13
- Reporting signal score
- 15.7159
- Event
- enterocolitis
- Reports
- 9
- Reporting signal score
- 16.6
- Event
- escherichia bacteraemia
- Reports
- 7
- Reporting signal score
- 18.5932
- Event
- fall
- Reports
- 3
- Reporting signal score
- 14.4032
- Event
- fatigue
- Reports
- 11
- Reporting signal score
- 20.363
- Event
- febrile bone marrow aplasia
- Reports
- 22
- Reporting signal score
- 60.8041
And 41 more, listed on the interactive page.
- NCT00111345
- NCT01015196
- NCT02277847
- NCT04190550
- NCT05955261
- NCT06221683
- NCT05280444
- Dose
- 12 mg/m2
- Route
- Intravenous
- How often
- Days 1, 2, and 3 of induction
Conditions of use
- Administer over 10 to 15 minutes
- Hydrogen bond acceptors
- 10
- Hydrogen bond donors
- 5
- Polar surface area
- 176.61
- Calculated partition coefficient (ALogP)
- 1.02
- Prodrug
- No
- Chirality
- Single enantiomer
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 3
- Heavy atoms
- 37
- Molecular formula
- C26H28ClNO9
- Monoisotopic mass
- 533.1452592
- Natural product
- Yes
- 0013-2576
- 0013-2586
- 0013-2596
- 0143-9217
- 0143-9218
- 0143-9219
- 0143-9306
- 0143-9307
- 0143-9308
- 71288-184
- 71288-185
- 71288-186
- Recorded assays
- 865
- Active assays
- 301
- Confirmatory
- Screening
- Summary
- Antibiotics, Antineoplastic
- Topoisomerase II Inhibitors
Related records
Trials (224)
- A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment
- A Phase II Study of Selinexor Plus Cytarabine and Idarubicin in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)
- A Randomized Study of Post-Remission Therapy in Elderly Patients With Acute Myelogenous Leukemia.
- A Safety and Efficacy Study of Ibrutinib in Pediatric and Young Adult Participants With Relapsed or Refractory Mature B-cell Non-Hodgkin Lymphoma
- A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations
- A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
- A Study of ASP2215 in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia.
- A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
- A Study of Children With Refractory or Relapsed ALL
- A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients With Acute Myeloid Leukaemia
- A Study of Indoximod in Combination With (7+3) Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia
- A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia
- A Study of RO5503781 as a Single Agent or in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia
- A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid Leukemia
- A Study of Volasertib Plus Induction Chemotherapy for Acute Myeloid Leukemia
- A Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia
- Adoptive Transfer of Haplo-identical DLI for AML and MDS
- Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to Frontline Induction Course
- AIDA2000 - Risk-Adapted Therapy for Patients With Acute Promyelocytic Leukemia
- Alisertib for Acute Myeloid Leukemia
Approved for (1)
In development for (2)
- Hepatocellular carcinoma Phase 2
- Myeloid leukemia Phase 2
Targets (1)
- TOP2A DNA topoisomerase II alpha inhibitor